Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MoneyHero

    MCap

    USD60m

    Last close

    USD2.35

    ▲ 0.55 (30.56%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oxford Cannabinoid Technologies (LSE: OCTP)

Last close As at 27/04/2024

GBP0.00

— 0.00 (0.00%)

Market capitalisation

GBP4m

Based in the UK, Oxford Cannabinoid Technologies is focused on advancing cannabinoid medicines for the treatment of pain and other indications. Lead asset OCT461201 is a CB2 selective agonist to be investigated for the treatment of neuropathic pain associated with CIPN and visceral pain in IBS as initial pain indications.

With the stigma that has become associated with opioids, alternative therapies for the treatment of pain are highly sought after. New drugs that target the endocannabinoid system may represent an innovative solution to address this need.

Latest Insights

View More

Healthcare | Update

Oxford Cannabinoid Technologies — Early signs of revival in clinical activity

Healthcare | edison tv

Oxford Cannabinoid Technologies – executive interview

Healthcare | Flash note

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Healthcare | Update

Oxford Cannabinoid Technologies — Clinical headway rests on funding
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Clarissa Sowemimo-Coker

    CEO

  • Paul Smalley

    CFO

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (15.1) (45.9) (70.8)
Relative (16.1) (49.1) (71.3)
52 week high/low 1.4p/0.3p

Financials

Oxford Cannabinoid Technologies (OCT) is focused on the development of endocannabinoid system-targeting new chemical entities (NCEs), phytocannabinoids (synthetic plant-derived cannabinoids) and synthetic cannabinoid derivatives. Lead asset OCT461201 is a cannabinoid receptor type 2 selective NCE agonist being developed as a potential treatment for neuropathic pain associated with chemotherapy-induced peripheral neuropathy and visceral pain in irritable bowel syndrome. OCT’s UK Phase I trial for OCT461201 concluded in October 2023 with no safety or tolerability concerns, but tight funding conditions have halted subsequent clinical progress. However, in January 2024 OCT announced a fund-raise for the development of its second asset, OCT130401 (an inhaled phytocannabinoid drug/device combination for trigeminal neuralgia); we expect Phase I to commence in Q2 CY24. OCT has two other programmes in earlier stages of development, targeting orphan and oncology indications.

Y/E Apr Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.0 (5.1) (5.1) (0.49) N/A N/A
2023A 0.0 (6.9) (7.0) (0.61) N/A N/A
2024E 0.0 (3.4) (3.4) (0.22) N/A N/A
2025E 0.0 (4.0) (4.0) (0.29) N/A N/A

Research

edison tv

Healthcare

Oxford Cannabinoid Technologies – executive interview

Flash note

Healthcare

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Healthcare

Update

Oxford Cannabinoid Technologies — Early signs of revival in clinical activity

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free